These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 25416753)

  • 21. Serum strain-specific or cross-reactive neuraminidase inhibiting antibodies against pandemic А/California/07/2009(H1N1) influenza in healthy volunteers.
    Desheva YA; Smolonogina TA; Donina SA; Rudenko LG
    BMC Res Notes; 2015 Apr; 8():136. PubMed ID: 25889924
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Epidemiology of 2009 pandemic influenza A virus subtype H1N1 among Kenyans aged 2 months to 18 years, 2009-2010.
    Wong KK; Bulimo WD; Magana J; Achilla RA; Schwarcz SK; Simwa M; Majanja JM; Wadegu MO; Osuna FA; Mukunzi SO; Mwangi JK; Wangui JM; Muthoni JN; Njiri JO; Obura BD; Opot BH; Mitei KK; Barani J; Lifumo S; Schnabel DC
    J Infect Dis; 2012 Dec; 206 Suppl 1():S68-73. PubMed ID: 23169975
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Molecular characterization of circulating pandemic strains of influenza A virus during 2012 to 2013 in Lucknow (India).
    Dangi T; Jain B; Singh AK; Singh JV; Kumar R; Dwivedi M; Verma AK; Chadha MS; Jain A
    J Med Virol; 2014 Dec; 86(12):2134-41. PubMed ID: 24777528
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Oseltamivir-zanamivir bitherapy compared to oseltamivir monotherapy in the treatment of pandemic 2009 influenza A(H1N1) virus infections.
    Escuret V; Cornu C; Boutitie F; Enouf V; Mosnier A; Bouscambert-Duchamp M; Gaillard S; Duval X; Blanchon T; Leport C; Gueyffier F; Van Der Werf S; Lina B
    Antiviral Res; 2012 Nov; 96(2):130-7. PubMed ID: 22909899
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of early oseltamivir therapy on viral shedding in 2009 pandemic influenza A (H1N1) virus infection.
    Ling LM; Chow AL; Lye DC; Tan AS; Krishnan P; Cui L; Win NN; Chan M; Lim PL; Lee CC; Leo YS
    Clin Infect Dis; 2010 Apr; 50(7):963-9. PubMed ID: 20180701
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pandemic Influenza A (H1N1) 2009 in India: duration of virus shedding in patients under antiviral treatment.
    Gandhoke I; Rawat DS; Rai A; Khare S; Ichhpujani RL
    Indian J Med Microbiol; 2011; 29(1):37-41. PubMed ID: 21304193
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Age-associated cross-reactive antibody-dependent cellular cytotoxicity toward 2009 pandemic influenza A virus subtype H1N1.
    Jegaskanda S; Laurie KL; Amarasena TH; Winnall WR; Kramski M; De Rose R; Barr IG; Brooks AG; Reading PC; Kent SJ
    J Infect Dis; 2013 Oct; 208(7):1051-61. PubMed ID: 23812238
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The response of medical virology laboratories to the influenza A(H1N1)pdm09 outbreak in Paris Île-de-France region.
    Seringe E; Agut H
    Pathol Biol (Paris); 2013 Oct; 61(5):203-8. PubMed ID: 23273748
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Genetic analysis of post-pandemic 2010-2011 influenza A(H1N1)pdm09 hemagglutinin virus variants that caused mild, severe, and fatal infections in Northern Greece.
    Melidou A; Gioula G; Exindari M; Chatzidimitriou D; Malisiovas N
    J Med Virol; 2015 Jan; 87(1):57-67. PubMed ID: 24898533
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effectiveness of monovalent 2009 pandemic influenza A virus subtype H1N1 and 2010-2011 trivalent inactivated influenza vaccines in Wisconsin during the 2010-2011 influenza season.
    Bateman AC; Kieke BA; Irving SA; Meece JK; Shay DK; Belongia EA
    J Infect Dis; 2013 Apr; 207(8):1262-9. PubMed ID: 23341536
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mild form of 2009 H1N1 influenza infection detected by active surveillance: implications for infection control.
    Jeong I; Lee CH; Kim DK; Chung HS; Park SW
    Am J Infect Control; 2010 Aug; 38(6):482-5. PubMed ID: 20416971
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Viral shedding duration of pandemic influenza A H1N1 virus during an elementary school outbreak--Pennsylvania, May-June 2009.
    Bhattarai A; Villanueva J; Palekar RS; Fagan R; Sessions W; Winter J; Berman L; Lute J; Leap R; Marchbanks T; Sodha SV; Moll M; Xu X; Fry A; Fiore A; Ostroff S; Swerdlow DL;
    Clin Infect Dis; 2011 Jan; 52 Suppl 1():S102-8. PubMed ID: 21342880
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A Synthetic Influenza Virus Vaccine Induces a Cellular Immune Response That Correlates with Reduction in Symptomatology and Virus Shedding in a Randomized Phase Ib Live-Virus Challenge in Humans.
    Pleguezuelos O; Robinson S; Fernández A; Stoloff GA; Mann A; Gilbert A; Balaratnam G; Wilkinson T; Lambkin-Williams R; Oxford J; Caparrós-Wanderley W
    Clin Vaccine Immunol; 2015 Jul; 22(7):828-35. PubMed ID: 25994549
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pandemic influenza A (H1N1) outbreak among 15 school-aged HIV-1-infected children.
    Feiterna-Sperling C; Edelmann A; Nickel R; Magdorf K; Bergmann F; Rautenberg P; Schweiger B; Wahn V; Krüger DH; Hofmann J
    Clin Infect Dis; 2010 Dec; 51(11):e90-4. PubMed ID: 21039216
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Reduced replication capacity of influenza A(H1N1)pdm09 virus during the 2010-2011 winter season in Tottori, Japan.
    Tsuneki A; Itagaki A; Tsuchie H; Tokuhara M; Okada T; Narai S; Kasagi M; Tanaka K; Kageyama S
    J Med Virol; 2013 Nov; 85(11):1871-7. PubMed ID: 23983181
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Delayed 2009 pandemic influenza A virus subtype H1N1 circulation in West Africa, May 2009-April 2010.
    Nzussouo NT; Michalove J; Diop OM; Njouom R; Monteiro Mde L; Adje HK; Manoncourt S; Amankwa J; Koivogui L; Sow S; Elkory MB; Collard JM; Dalhatu I; Niang MN; Lafond K; Moniz F; Coulibaly D; Kronman KC; Oyofo BA; Ampofo W; Tamboura B; Bara AO; Jusot JF; Ekanem E; Sarr FD; Hwang I; Cornelius C; Coker B; Lindstrom S; Davis R; Dueger E; Moen A; Widdowson MA
    J Infect Dis; 2012 Dec; 206 Suppl 1():S101-7. PubMed ID: 23169954
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The environmental deposition of influenza virus from patients infected with influenza A(H1N1)pdm09: Implications for infection prevention and control.
    Killingley B; Greatorex J; Digard P; Wise H; Garcia F; Varsani H; Cauchemez S; Enstone JE; Hayward A; Curran MD; Read RC; Lim WS; Nicholson KG; Nguyen-Van-Tam JS
    J Infect Public Health; 2016; 9(3):278-88. PubMed ID: 26653976
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and tolerability of the oral neuraminidase inhibitor peramivir in experimental human influenza: randomized, controlled trials for prophylaxis and treatment.
    Barroso L; Treanor J; Gubareva L; Hayden FG
    Antivir Ther; 2005; 10(8):901-10. PubMed ID: 16430195
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A randomized clinical trial to identify the optimal antigen and MF59(®) adjuvant dose of a monovalent A/H1N1 pandemic influenza vaccine in healthy adult and elderly subjects.
    Hatz C; von Sonnenburg F; Casula D; Lattanzi M; Leroux-Roels G
    Vaccine; 2012 May; 30(23):3470-7. PubMed ID: 22446638
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Characterization of oseltamivir-resistant influenza A(H1N1)pdm09 viruses in Taiwan in 2009-2011.
    Yang JR; Huang YP; Chang FY; Hsu LC; Huang HY; Pan YT; Lin YC; Wu HS; Liu MT
    J Med Virol; 2013 Mar; 85(3):379-87. PubMed ID: 23280715
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.